Communiqués Theratechnologies Inc. Nasdaq

Actions

THTX

CA88338H7040

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
1,535 ^USD	-2,69%		+2,33%	-5,25%

10/07	Theratechnologies inc. annonce ses résultats pour le deuxième trimestre et les six mois terminés le 31 mai 2024	CI
10/07	Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Theratechnologies: Fiscal Q2 Earnings Snapshot	10/07	AQ
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024	10/07	AQ
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update	26/06	AQ
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors	23/05	AQ
Theratechnologies Reports on its Annual Meeting of Shareholders	09/05	AQ
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting	02/05	AQ
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	15/04	AQ
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	11/04	AQ
Theratechnologies: Fiscal Q1 Earnings Snapshot	10/04	AQ
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024	10/04	AQ
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform	08/04	AQ
Theratechnologies Appoints Elina Tea to its Board of Directors	05/04	AQ
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update	03/04	AQ
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform	28/03	AQ
Theratechnologies Announces Update on its Preclinical Oncology Research Program	22/03	AQ
Theratechnologies Appoints Jordan Zwick to its Board of Directors	22/03	AQ
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	21/03	AQ
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau	29/02	AQ
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA	27/02	AQ
Theratechnologies: Fiscal Q4 Earnings Snapshot	21/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Theratechnologies Inc. Nasdaq

Actions

THTX

CA88338H7040

Communiqués

Filtres